Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Consort, Opiant to develop nasal spray for opioid overdose treatment

Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.

Read More »

Emergent BioSolutions to buy Narcan maker Adapt Pharma

Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.

Read More »

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department joined several whistleblower lawsuits against Indivior and Reckitt Benckiser Group, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Read More »

FDA Issues New Draft Guidance to Promote Development of Medications to Treat Opioid Use Disorder

The U.S. Food and Drug Administration issued a new draft guidance for the development of novel medicines aimed at the treatment of opioid use disorder.

Read More »

Indivior: U.S. court rules against generic rival’s appeal

Indivior Plc notched a legal victory after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker’s best-selling opioid addiction treatment in the United States.

Read More »

U.S. court expedites Indivior rival’s appeal to re-launch generic drug

Indivior said a U.S. court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid addiction treatment.

Read More »

U.S. court blocks sale of Indivior rival generic

Indivior Plc’s shares jumped more than 33 percent after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.

Read More »

U.S. Food and Drug Administration Clears Wearable Device to Treat Opioid Addiction

DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.

Read More »

Most Americans miss out on preventive healthcare

Very few U.S. adults receive all the preventive health care services recommended for them, reports a new study.

Read More »

Indivior subpoenaed by California on opioid addiction treatment

Britain’s Indivior was subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom